Synektik S.A. logo

Synektik S.A. (SNT)

Market Closed
12 Jun, 14:50
WSE WSE
292. 60
+15.8
+5.7081%
- Market Cap
- P/E Ratio
- Div Yield
57,201 Volume
- Eps
276.8
Previous Close
Add Transaction
Day Range
280.2 292.8
Year Range
180.2 317
Want to track SNT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SNT closed today higher at zł292.6, an increase of 5.7081% from yesterday's close, completing a monthly increase of 5.3276% or zł14.8. Over the past 12 months, SNT stock gained 1.8093%.
SNT pays dividends to its shareholders, with the most recent payment made on Feb 02, 2026. The next estimated payment will be in In 7 months on Feb 02, 2027 for a total of zł10.75.
The last earnings report, released on Jun 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on WSE (PLN).

SNT Chart

Synektik S.A. (SNT) FAQ

What is the stock price today?

The current price is zł292.60.

On which exchange is it traded?

Synektik S.A. is listed on WSE.

What is its stock symbol?

The ticker symbol is SNT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Synektik S.A. ever had a stock split?

No, there has never been a stock split.

Synektik S.A. Profile

Biotechnology Industry
Healthcare Sector
- CEO
WSE Exchange
PLSNKTK00019 ISIN
Poland Country
165 Employees
28 Jan 2026 Last Dividend
- Last Split
- IPO Date

Overview

Synektik S.A. is a leading entity in the medical technology realm, with a major emphasis on the innovation and provision of radiopharmaceuticals and medical equipment. Positioned at the forefront of the healthcare sector, the company excels in crafting groundbreaking solutions tailored for diagnostic imaging and radiation oncology. Through its dedicated efforts, Synektik S.A. significantly enhances the precision of diagnoses and treatments, profoundly impacting patient care efficacy. The company captures a critical market role by responding to the escalating demands for sophisticated diagnostic methods and individualized treatment approaches, mirroring the healthcare industry’s shift towards more directed and efficacious therapies. Synektik S.A.'s steadfast partnerships with healthcare providers and research entities underscore its crucial contribution to the evolution of medical technology and the improvement of patient outcomes globally.

Products and Services

  • Radiopharmaceuticals and Isotopes
  • Synektik S.A. specializes in the development and supply of radiopharmaceuticals and isotopes, fundamental for nuclear medicine procedures. These products are used in diagnostic imaging to detect and treat various diseases, enabling physicians to diagnose conditions accurately and decide on the most appropriate treatment plans.

  • Medical Imaging Systems
  • The company distributes advanced medical imaging systems, including MRI and CT scanners, essential for non-invasive diagnostic procedures. These systems play a crucial role in today's healthcare by offering detailed images of the human body, aiding in the early detection and treatment of diseases.

  • Innovative Solutions for Diagnostic Imaging and Radiation Oncology
  • With a focus on improving diagnostic accuracy and treatment precision, Synektik S.A. provides innovative solutions tailored for the fields of diagnostic imaging and radiation oncology. This encompasses a range of products and technologies designed to enhance the effectiveness of patient care, from advanced imaging techniques to targeted radiation therapy options.

Contact Information

Address: ul. JOzefa Piusa Dziekonskiego 3
Phone: 48 22 327 0900